JP2006521111A5 - - Google Patents

Download PDF

Info

Publication number
JP2006521111A5
JP2006521111A5 JP2006507160A JP2006507160A JP2006521111A5 JP 2006521111 A5 JP2006521111 A5 JP 2006521111A5 JP 2006507160 A JP2006507160 A JP 2006507160A JP 2006507160 A JP2006507160 A JP 2006507160A JP 2006521111 A5 JP2006521111 A5 JP 2006521111A5
Authority
JP
Japan
Prior art keywords
ephb4
shows
ephrin
seq
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006507160A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006521111A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/007755 external-priority patent/WO2004080425A2/en
Publication of JP2006521111A publication Critical patent/JP2006521111A/ja
Publication of JP2006521111A5 publication Critical patent/JP2006521111A5/ja
Pending legal-status Critical Current

Links

Images

JP2006507160A 2003-03-12 2004-03-12 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用 Pending JP2006521111A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45430003P 2003-03-12 2003-03-12
US45443203P 2003-03-12 2003-03-12
PCT/US2004/007755 WO2004080425A2 (en) 2003-03-12 2004-03-12 Polypeptide compounds for inhibiting angiogenesis and tumor growth

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011157200A Division JP2011256179A (ja) 2003-03-12 2011-07-15 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用

Publications (2)

Publication Number Publication Date
JP2006521111A JP2006521111A (ja) 2006-09-21
JP2006521111A5 true JP2006521111A5 (cg-RX-API-DMAC7.html) 2007-05-24

Family

ID=32994555

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006507095A Expired - Fee Related JP4762889B2 (ja) 2003-03-12 2004-03-12 血管形成及び腫瘍成長を阻止するための核酸化合物
JP2006507160A Pending JP2006521111A (ja) 2003-03-12 2004-03-12 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用
JP2011157200A Pending JP2011256179A (ja) 2003-03-12 2011-07-15 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006507095A Expired - Fee Related JP4762889B2 (ja) 2003-03-12 2004-03-12 血管形成及び腫瘍成長を阻止するための核酸化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011157200A Pending JP2011256179A (ja) 2003-03-12 2011-07-15 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用

Country Status (6)

Country Link
US (5) US7585967B2 (cg-RX-API-DMAC7.html)
EP (2) EP1605961A4 (cg-RX-API-DMAC7.html)
JP (3) JP4762889B2 (cg-RX-API-DMAC7.html)
AU (3) AU2004220525B2 (cg-RX-API-DMAC7.html)
CA (2) CA2518898A1 (cg-RX-API-DMAC7.html)
WO (2) WO2004080425A2 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887674B1 (en) * 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
AU2002951409A0 (en) * 2002-09-16 2002-09-26 North Western Adelaide Health Services Methods for regulating cancer
JP2006507256A (ja) 2002-09-24 2006-03-02 ザ バーナム インスティチュート Eph受容体活性を調節する新規薬剤
EP1605961A4 (en) 2003-03-12 2009-11-11 Vasgene Therapeutics Inc POLYPEPTIDE COMPOUNDS FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
KR20120123619A (ko) 2004-03-12 2012-11-08 바스진 테라퓨틱스, 인크. 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물
WO2005090406A2 (en) * 2004-03-12 2005-09-29 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
JP2007320850A (ja) * 2004-08-24 2007-12-13 Kyowa Hakko Kogyo Co Ltd 抗エフリンb2抗体
WO2006034455A2 (en) * 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
AU2005286663A1 (en) * 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Compositions and methods for detecting and treating tumors
DE102004054016A1 (de) * 2004-11-09 2006-05-11 Robert Bosch Gmbh Steuergerät zum Steuern und/oder regeln mindestens einer Fahrzeugfunktion
CA2587854C (en) * 2004-11-18 2014-01-21 The Board Of Trustees Of The University Of Illinois Multicistronic sirna constructs to inhibit tumors
WO2006074392A2 (en) * 2005-01-06 2006-07-13 Genentech, Inc. Cancer prognostic, diagnostic and treatment methods
WO2006081418A2 (en) * 2005-01-27 2006-08-03 The Burnham Institute Ephb receptor-binding peptides
FR2889200B1 (fr) 2005-07-27 2008-01-04 Inst Vaisseaux Et Du Sang Ass Systeme marqueur cellulaire/ligand, ou le marqueur est du type eph, materiau cellulaire comprenant ce systeme, procede de preparation et utilisation proangiogenique
EP1937291A2 (en) * 2005-09-23 2008-07-02 Vasgene Therapeutics, Inc. Use of ephrinb2 directed agents for the treatment of prevention of viral infections
RU2451031C2 (ru) 2006-01-20 2012-05-20 Дженентек, Инк. Антитела к эфрину в2 и способы их применения
JP2010500011A (ja) 2006-08-08 2010-01-07 ガンサー ハートマン 5’リン酸オリゴヌクレオチドの構造および使用
US20110052667A1 (en) * 2007-06-28 2011-03-03 Sylgen Laboratories, Inc. Compositions and methods for inhibiting angiogenesis and tumorigenesis
CN102083861B (zh) * 2007-08-13 2016-04-13 瓦斯基因治疗公司 使用结合EphB4的人源化抗体的癌症治疗
US8357501B2 (en) 2007-11-29 2013-01-22 Molecular Health Gmbh Tissue protective erythropoietin receptor (NEPOR) and methods of use
ATE554186T1 (de) * 2007-11-29 2012-05-15 Molecular Health Gmbh Eph-b4 spezifische sirna zur reduktion von epo- induziertem tumorzellwachstum während anämiebehandlung in krebspatienten, gewebeschutz- erythropoietin-rezeptor (nepor) und verfahren zu seiner verwendung
US9738680B2 (en) 2008-05-21 2017-08-22 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
WO2012112434A1 (en) * 2011-02-14 2012-08-23 Allergan, Inc. Inhibiting aberrant blood vessel formation using retargeted endopeptidases
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
JP2015071566A (ja) * 2013-10-03 2015-04-16 住友ベークライト株式会社 Fgf4遺伝子増幅腫瘍の医薬組成物
US12655390B2 (en) 2016-12-14 2026-06-16 Shinshu University Chimeric antigen receptor gene-modified lymphocyte having cytocidal effect
WO2018110374A1 (ja) * 2016-12-14 2018-06-21 国立大学法人信州大学 殺細胞効果を有するキメラ抗原受容体遺伝子改変リンパ球
US20200224239A1 (en) * 2019-01-10 2020-07-16 Massachusetts Institute Of Technology Functional analysis of cancer cells
US12560590B2 (en) 2019-01-23 2026-02-24 Massachusetts Institute Of Technology Rapid analysis of live cells
AU2020241963B2 (en) 2019-03-17 2026-07-02 Vasgene Therapeutics Inc Treatment of cancers using sEphB4-HSA fusion proteins
WO2021242637A1 (en) * 2020-05-28 2021-12-02 Cytobay Inc. Cytopathological staining
EP4105328A1 (en) * 2021-06-15 2022-12-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Antisense-oligonucleotides for prevention of kidney dysfunction promoted by endothelial dysfunction by ephrin-b2 suppression
US20250339504A1 (en) * 2022-05-18 2025-11-06 National Cancer Center Cancer vaccine with use of common cancer antigen cocktail, tcr/car-t cell therapeutic, companion diagnostic method, and method for diagnosing risk of cancer onset by detecting circulating tumor cells

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
ATE278019T1 (de) 1991-06-21 2004-10-15 Inst Medical W & E Hall Neuartige rezeptor-typ tyrosinkinase und deren verwendung
JPH07504813A (ja) 1992-01-22 1995-06-01 ニユー・イングランド・デイーコネス・ホスピタル 新規蛋白質チロシンキナーゼ類
US6331302B1 (en) * 1992-01-22 2001-12-18 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5635177A (en) 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
KR100335584B1 (ko) 1992-10-28 2002-11-29 제넨테크, 인코포레이티드 혈관내피세포성장인자에대한길항제
FI952328A7 (fi) 1992-11-13 1995-07-10 Amgen Inc eck-respetorin lignandeja
US5824303A (en) * 1992-11-13 1998-10-20 Amgen Inc. Eck receptor ligands
US5512591A (en) * 1993-02-18 1996-04-30 President And Fellows Of Harvard College Treatments for diseases characterized by neovascularization
ES2152753B1 (es) 1993-03-29 2001-09-01 Ct Investig Energeticas Ciemat Animales transgenicos para la determinacion de agentes que estimulan o reprimen la hiperproliferacion epidermica y el crecimiento del pelo
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US6303769B1 (en) * 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5864020A (en) * 1994-07-20 1999-01-26 Genentech, Inc. HTK ligand
AU3144195A (en) 1994-07-26 1996-02-22 Rutgers, The State University Of New Jersey Human brain specific kinase
US5795734A (en) 1994-09-19 1998-08-18 President And Fellows Of Harvard College EPH receptor ligands, and uses related thereto
WO1996013518A1 (en) 1994-10-27 1996-05-09 Genentech, Inc. Al-1 neurotrophic factor, a ligand for an eph-related tyrosine kinase receptor
US6057124A (en) 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
WO1996026958A2 (en) 1995-02-27 1996-09-06 President And Fellows Of Harvard College Eph RECEPTOR LIGAND ELF-2
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
PT848755E (pt) 1995-09-08 2003-12-31 Genentech Inc Proteina relacionada com o vegf
US6346398B1 (en) * 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US5837534A (en) * 1995-11-14 1998-11-17 The Board Of Regents Of The University Of Texas System Smooth muscle 22α promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells
AUPN727795A0 (en) 1995-12-22 1996-01-18 Walter And Eliza Hall Institute Of Medical Research, The A novel receptor-type tyrosine kinase and use thereof
US6696557B1 (en) * 1996-04-19 2004-02-24 Genentech, Inc. AL-2 neurotrophic factor nucleic acid
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
CA2259157A1 (en) * 1996-07-05 1998-01-15 Mount Sinai Hospital Corporation Oligomerized receptors which affect pathways regulated by transmembrane ligands for elk-related receptor tyrosine kinases
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
AU6887698A (en) 1997-04-08 1998-10-30 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
US6440954B1 (en) * 1997-04-18 2002-08-27 President And Fellows Of Harvard College Inhibition of vascular smooth muscle cell proliferation
US6555321B1 (en) * 1997-08-19 2003-04-29 Vanderbilt University Methods for determining cell responses through EphB receptors
EP1019080A2 (en) 1997-10-02 2000-07-19 Leukosite, Inc. Modulation of lerk-2-mediated cell adhesion
DE69921102T2 (de) * 1998-03-05 2006-02-02 Chiron Corp., Emeryville Verfahren zur verbesserung der serum-halbwertszeit von biologisch aktiven molekülen
US6887674B1 (en) * 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6864227B1 (en) * 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
AU8788998A (en) 1998-10-02 2000-04-06 Universite Paris 7 Vascular specific regulatory elements contained in the desmin 5' flanking region
AUPP674898A0 (en) 1998-10-27 1998-11-19 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment
ES2242437T3 (es) * 1998-11-20 2005-11-01 Genentech, Inc. Utilizaciones de agonistas y antagonistas del receptor eph para el tratamiento de trastornos vasculares.
US6150162A (en) * 1998-12-17 2000-11-21 Isis Pharmaceuticals Inc. Antisense modulation of CD44 expression
US6770633B1 (en) * 1999-10-26 2004-08-03 Immusol, Inc. Ribozyme therapy for the treatment of proliferative skin and eye diseases
EP1246637A2 (en) 2000-01-06 2002-10-09 The Hospital for Sick Children Methods of modulation of the immune system
CA2400573A1 (en) * 2000-03-28 2001-10-04 Isis Pharmaceuticals Inc. Alteration of cellular behavior by antisense modulation of mrna processing
US6926898B2 (en) * 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
JP2003530871A (ja) 2000-04-21 2003-10-21 アムジエン・インコーポレーテツド インテグリン/接着因子アンタゴニスト
US6271030B1 (en) * 2000-06-14 2001-08-07 Isis Pharmaceuticals, Inc. Antisense inhibition of C/EBP beta expression
US6277640B1 (en) * 2000-07-31 2001-08-21 Isis Pharmaceuticals, Inc. Antisense modulation of Her-3 expression
CA2417982A1 (en) 2000-08-03 2002-02-14 The University Of Utah Research Foundation Manipulation of arterial-venous identity
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
WO2002026827A1 (en) 2000-09-29 2002-04-04 Novartis Ag Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules
US7136808B2 (en) * 2000-10-20 2006-11-14 Microsoft Corporation Detection and correction of errors in german grammatical case
DE60127291T2 (de) * 2000-11-20 2007-12-20 California Institute Of Technology, Pasadena Für den glatten muskel von arterien und den glatten muskel von venen spezifische proteine und deren verwendung
CN100523215C (zh) * 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
US6958140B2 (en) 2001-01-26 2005-10-25 Regeneron Pharmaceuticals, Inc. Methods of imaging and targeting vasculature
US20040132634A1 (en) 2001-01-31 2004-07-08 Frank Sicheri Compositions and methods for regulating the kinase domain of receptor tyrosine kinases
JP2004517638A (ja) 2001-02-02 2004-06-17 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 機能的核酸の同定方法
CA2442092A1 (en) * 2001-03-26 2002-10-17 Ribozyme Pharmaceuticals, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
WO2002079382A2 (en) 2001-03-30 2002-10-10 President And Fellows Of Harvard College B-ephrin regulation of g-protein coupled chemoattraction; compositions and methods of use
EP1386004A4 (en) * 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
JP2005500025A (ja) * 2001-05-29 2005-01-06 サーナ・セラピューティクス・インコーポレイテッド 女性生殖疾病及び状態の核酸に基づく調節
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
EP1409549A4 (en) * 2001-06-20 2007-10-24 Genentech Inc COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS
US20040247592A1 (en) * 2001-07-03 2004-12-09 Roifman Chaim M. Ephrin and eph receptor mediated immune modulation
JP3876656B2 (ja) * 2001-07-13 2007-02-07 住友金属工業株式会社 管用ねじ継手
JP2005531281A (ja) * 2001-11-02 2005-10-20 ファイザー・プロダクツ・インク 肺癌の治療および診断
US20060241027A1 (en) * 2002-02-07 2006-10-26 Hans-Peter Hauser Hiv inhibiting proteins
EP1519956B1 (en) 2002-05-10 2011-09-21 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
EP1575509B1 (en) 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
US20040110150A1 (en) * 2002-12-10 2004-06-10 Isis Pharmaceuticals Inc. Modulation of Ephrin-B2 expression
WO2004020468A2 (en) 2002-08-28 2004-03-11 Maxygen Aps Interferon beta-like molecules for treatment of cancer
AU2003260169B9 (en) * 2002-09-16 2011-06-09 The Queen Elizabeth Hospital Research Foundation Inc. Methods for regulating cancer
AU2002951409A0 (en) 2002-09-16 2002-09-26 North Western Adelaide Health Services Methods for regulating cancer
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
US7250289B2 (en) * 2002-11-20 2007-07-31 Affymetrix, Inc. Methods of genetic analysis of mouse
EP1605961A4 (en) * 2003-03-12 2009-11-11 Vasgene Therapeutics Inc POLYPEPTIDE COMPOUNDS FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH
NZ543122A (en) * 2003-03-24 2008-07-31 Sequoia Pharmaceuticals Inc An HIV fusion inhibitor peptide covalently linked to a blood protein
EP1618184A4 (en) * 2003-04-11 2006-06-21 Medimmune Inc EPHA2, HYPOPROLIFERATIVE CELL DISORDERS, AND EPITHELIAL AND ENDOTHELIAL RECONSTITUTION
EP1617864A4 (en) 2003-04-11 2006-06-21 Medimmune Inc EPHA2 AND NON-NEOPLASTIC HYPERPROLIFERATIVE CELL TROUBLESHOOTING
WO2005048917A2 (en) 2003-06-06 2005-06-02 Medimmune, Inc. Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer
DK1677735T3 (da) * 2003-10-17 2014-10-27 Joslin Diabetes Center Inc Fremgangsmåder og sammensætninger til modulering af adipocytfunktion
KR20060135671A (ko) 2003-11-20 2006-12-29 메디뮨 인코포레이티드 EphA2 작동성 모노클로날 항체 및 이의 사용 방법
WO2005090406A2 (en) 2004-03-12 2005-09-29 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2006034455A2 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth

Similar Documents

Publication Publication Date Title
EP1429797B1 (en) Diagnosis and treatment of malignant neoplasms
JP4375932B2 (ja) 悪性新生物の診断および処置
JP4762889B2 (ja) 血管形成及び腫瘍成長を阻止するための核酸化合物
KR100304033B1 (ko) 세포증식질환치료용약제학적조성물
Wang et al. Antisense targeting of basic fibroblast growth factor and dibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth
Maeshima et al. Inhibition of mesangial cell proliferation by E2F decoy oligodeoxynucleotide in vitro and in vivo.
JP4205136B2 (ja) サブトラクションcDNAライブラリーの作製方法および該作製されたライブラリーの使用
Wang et al. p75NTR mediates neurotrophin-induced apoptosis of vascular smooth muscle cells
JP4698837B2 (ja) 結合組織成長因子(ctgf)および使用方法
JP3844501B2 (ja) 癌の制御
JP2002505841A (ja) 低酸素調節性遺伝子
US7381410B2 (en) Polypeptide compounds for inhibiting angiogenesis and tumor growth
JP2002525081A (ja) 低酸素により調節される遺伝子転写に特徴的な配列
JP3398149B2 (ja) Mts―1遺伝子による転移性の癌の診断
JPH09502094A (ja) 老化細胞由来dna合成阻害因子
JP2003501345A (ja) 勃起不全の治療における血管内皮成長因子の使用
CN101712960A (zh) Mac-2BP肿瘤抗原基因、蛋白、抗体及其用途
WO2000034466A1 (en) Cervical cancer treatment
WO2001019967A1 (en) Human inflammatory breast carcinoma xenograft capable of lymphovascular invasion and methods for its use
US6140119A (en) Expression of estrogen receptors in type I and type II human breast epithelial cells
WO2006123644A1 (ja) 低酸素ストレス応答に関与するInt6タンパク質、およびその利用
HK1112510A (en) Diagnosis and treatment of malignant neoplasms
WO2018133733A1 (zh) 一种靶向rna解旋酶dhx33的小分子rna及其应用
JPWO2000022123A1 (ja) 新規なタンパク質war−1及びその遺伝子
CA2321189A1 (en) Antisense oligonucleotides directed toward mammalian vegf receptor genes and uses thereof